Stakeholders Urge Major Changes To PBS Listing Guidelines
This article was originally published in Scrip
Executive Summary
The future shape of Australia's system for listing medicines on the Pharmaceutical Benefits Scheme (PBS) is becoming clearer after the government published stakeholder responses to a consultation on the long-awaited review of the Pharmaceutical Benefits Advisory Committee (PBAC) guidelines, which are used by the pharmaceutical industry to prepare requests for PBS listing.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.